Humacyte annual free cash flow
2020
2021
2022
2023
2024
2025
Humacyte Free Cash Flow (FCF) History (HUMA)
Humacyte reported −$105.9M in free cash flow for fiscal 2025, a decrease of $6.2M from the previous fiscal year, with a free cash flow margin of −5197.55%.
View full Humacyte company overviewHumacyte free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$105.9M | −$6.2M | — | −5197.55% |
| 2024 | 2024-12-31 | −$99.7M | −$24.1M | — | — |
| 2023 | 2023-12-31 | −$75.6M | −$3.4M | — | — |
| 2022 | 2022-12-31 | −$72.2M | $9.2M | — | — |
| 2021 | 2021-12-31 | −$81.4M | −$25.5M | — | — |
| 2020 | 2020-12-31 | −$55.9M | — | — | — |
Humacyte quarterly free cash flow
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$22.2M | $4.8M | — | −5459.36% |
| Q1 2026 | 2026-03-31 | −$25.3M | $3.5M | — | −5106.87% |
| Q4 2025 | 2025-12-31 | −$26.2M | $477,000 | — | −5602.36% |
| Q3 2025 | 2025-09-30 | −$24.0M | −$112,000 | — | −3181.01% |
| Q2 2025 | 2025-06-30 | −$27.0M | −$5.5M | — | −8963.79% |
| Q1 2025 | 2025-03-31 | −$28.8M | −$1.1M | — | −5576.21% |
| Q4 2024 | 2024-12-31 | −$26.6M | −$7.4M | — | — |
| Q3 2024 | 2024-09-30 | −$23.8M | −$10.3M | — | — |
| Q2 2024 | 2024-06-30 | −$21.5M | $1.6M | — | — |
| Q1 2024 | 2024-03-31 | −$27.7M | −$7.9M | — | — |
| Q4 2023 | 2023-12-31 | −$19.2M | $436,000 | — | — |
| Q3 2023 | 2023-09-30 | −$13.5M | $3.5M | — | — |
| Q2 2023 | 2023-06-30 | −$23.1M | −$6.4M | — | — |
| Q1 2023 | 2023-03-31 | −$19.8M | −$974,000 | — | — |
| Q4 2022 | 2022-12-31 | −$19.6M | $1.9M | — | — |
| Q3 2022 | 2022-09-30 | −$17.0M | $13.6M | — | — |
| Q2 2022 | 2022-06-30 | −$16.7M | −$2.0M | — | — |
| Q1 2022 | 2022-03-31 | −$18.8M | −$4.2M | — | — |
| Q4 2021 | 2021-12-31 | −$21.5M | — | — | — |
| Q3 2021 | 2021-09-30 | −$30.6M | — | — | −12697.93% |
| Q2 2021 | 2021-06-30 | −$14.7M | — | — | — |
| Q1 2021 | 2021-03-31 | −$14.6M | — | — | — |
Humacyte free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$55.9M to −$105.9M, a net decrease of $50.0M. Humacyte's latest reported quarter, Q2 2026, generated −$22.2M in free cash flow, an increase of $4.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Humacyte filings at SEC.gov ↗